Evidence map›Paper›PMID 39005610›Full record

ArticleIranian journal of microbiology2024

Secondary bacterial infections in post-COVID-19 mucormycosis cases: a retrospective study at Imam Khomeini Hospital Complex, March 2020-April 2021.

Mohsen Meidani, Sepideh Zahak Miandoab, Amir Salami, Sajedeh Jadidi, Marjan Sohrabi, Parvaneh Ebrahimi Alavijeh, Sara Ghaderkhani, Hamid Emadi Koochak, Arezoo Salami Khaneshan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohsen MeidaniDepartment of Infectious Disease and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sepideh Zahak MiandoabDepartment of Infectious Disease and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amir SalamiStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Sajedeh JadidiDepartment of Urology, Shahid Beheshti University of Medical Sciences, Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Tehran, Iran.
Marjan SohrabiDepartment of Infectious Disease and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Parvaneh Ebrahimi AlavijehDepartment of Infectious Disease and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sara GhaderkhaniDepartment of Infectious Disease and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Hamid Emadi KoochakDepartment of Infectious Disease and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Arezoo Salami KhaneshanDepartment of Infectious Disease and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: To explore the prevalence and characteristics of secondary bacterial infections among patients suffering from mucormycosis following COVID-19 infection. Materials and Methods: We conducted a cross-sectional, retrospective analysis from March 2020 to April 2022 at Imam Khomeini Hospital Complex in Tehran. The study included patients with histopathologically confirmed mucormycosis and documented secondary bacterial infections. We extracted and analyzed data from hospital records using SPSS software, version 26. Results: The study comprised 27 patients, with a predominance of females (70.4%) and an average age of 56 years. The majority of these patients (63%) had pre-existing diabetes mellitus. The severity of their COVID-19 infections varied. Treatment regimens included immunosuppressive drugs and antibiotics. Rhinocerebral mucormycosis was the most common form observed. The predominant secondary infections involved the urinary tract, respiratory system, bloodstream (bacteremia), and soft tissues, with resistant strains of Conclusion: Patients recovering from COVID-19 with mucormycosis are significantly susceptible to secondary bacterial infections, particularly those with diabetes mellitus or those undergoing immunosuppressive therapy. Such infections compound the morbidity and mortality risks in this vulnerable patient cohort.

Indexed as

Acinetobacter baumanniiBacterial infectionCOVID-19Escherichia coliKlebsiella pneumoniaMucormycosis

Identifiers

PMID39005610
PMCPMC11245346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.